CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
ANK-700 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04602390
NCT04602390Phase 1Completed
CompareCT.gov

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Anokion SA·interventional·Posted Oct 26, 2020·Updated May 31, 2025

In Brief

A Phase 1 clinical trial evaluating ANK-700 and Placebo for Multiple Sclerosis (MS) and Relapsing Remitting Multiple Sclerosis. Completed, enrolled 34 participants across 15 sites.

Detailed Summary

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedOct 26, 2020
Enrollment StartNov 6, 2020
Primary CompletionApr 23, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.7 years ago

Interventions

ANK-700drug

Intravenous (IV) infusion

Placebodrug

Intravenous (IV) infusion